Premium
SU‐E‐T‐472: Personalized 3D Dose Prediction for Intrabeam Treatments Based On Patient CT Imaging with Monte Carlo GATE Simulations
Author(s) -
Bouzid D,
Nicolas B,
Dupre P,
Bert J,
Pradier O,
Visvikis D
Publication year - 2013
Publication title -
medical physics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.473
H-Index - 180
eISSN - 2473-4209
pISSN - 0094-2405
DOI - 10.1118/1.4814905
Subject(s) - thermoluminescent dosimeter , dosimeter , nuclear medicine , dosimetry , context (archaeology) , monte carlo method , medicine , medical imaging , radiation therapy , medical physics , radiology , mathematics , paleontology , statistics , biology
Purpose: The aim of partial breast irradiation is to reduce the risk of local recurrence into the tumor bed. After surgical resection of the tumor, the Intrabeam™ system delivers a single dose fraction of 20 Gy at the surface of the applicator, irradiating the tumor bed through a 50keV X‐ray beam. However, there is currently no latitude for personalized dose prescription which is in contrast to official recommendations for individual dose optimization in radiotherapy. In this context, the study aim was to perform personalized 3D dose prediction for Intrabeam™ treatments based on patient CT imaging using Monte Carlo (MC) simulations. Methods: A model of the Intrabeam™ system was developed with GATE taking into account the different parts of the device. A preoperative CT acquisition of the patient breast is performed and included in the simulation allowing accurate dose calculation. During intra‐operative radiotherapy, thermo‐luminescent dosimeters are placed on the skin at 1 and 3 cm around the spherical applicator. Comparison between simulation results and TLD measurements are performed to confirm the dose prediction at the TLD locations. This study was performed on 10 patients, including 3 who had an intra‐operative CT acquisition in order to validate the overall dosimetry evaluation protocol. Results: Patient results show good agreement between clinical experiments and simulations. Indeed the relative mean deviation between TLD dose measurements and GATE dose scoring is 0.09% ± 0.11% with a maximum of 0.334% and less than 1% of dose estimation uncertainty (min 0.41% max 0.95%). Conclusion: We propose the use of an accurate model of the Intrabeam system on the GATE platform based on Geant4 MC toolkit. The dosimetric evaluation of the proposed platform with patient datasets supports its use for patient specific dosimetry planning.